An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

(2021) Kyung‐Sang Yu et al.   CTS-Clinical and Translational Science

Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis

(2020) Kelly A. Reynolds et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

(2020) Jinmei Su et al.   BIODRUGS

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

(2020) Liese Barbier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis

(2020) Antonella Di Cesare et al.   Dermatologic Therapy

Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases

(2020) Cosimo Bruni et al.   CLINICAL RHEUMATOLOGY

PF-06410293: An Adalimumab Biosimilar

(2020) Arnold Lee et al.   BIODRUGS

Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

(2020) Valdemar Wendelboe Nielsen et al.   Dermatologic Therapy

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

(2019) Oliver von Richter et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States

(2019) A. Teeple et al.   CURRENT MEDICAL RESEARCH AND OPINION

AURIEL ‐PsO: A randomised, double‐blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

(2019) J. Hercogová et al.   BRITISH JOURNAL OF DERMATOLOGY

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis

(2019) Paolo Gisondi et al.   CURRENT OPINION IN PHARMACOLOGY

Biosimilars for the treatment of psoriasis

(2019) Lluís Puig et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

(2019) Christopher J. Edwards et al.   CLINICAL RHEUMATOLOGY

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

(2019) Stanley B. Cohen et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

(2018) Stanley B Cohen et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

(2018) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

(2018) Michael E. Weinblatt et al.   Arthritis & Rheumatology

A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers

(2017) D. Shin et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

(2017) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Therapy: Biosimilars in rheumatology — why, how and when in 2017

(2017) Roy Fleischmann   Nature Reviews Rheumatology

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

(2016) Hillel Cohen et al.   ADVANCES IN THERAPY

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

(2016) Primal Kaur et al.   ANNALS OF THE RHEUMATIC DISEASES

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

(2016) Christopher Wynne et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study

(2015) G. Palareti et al.   International Journal of Laboratory Hematology

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

(2015) Rajendrakumar H. Jani et al.   International Journal of Rheumatic Diseases

Budget Impact Analysis of An Etanercept Biosimilar for The Treatment of Rheumatoid Arthritis In Europe

(2015) L Ruff et al.   VALUE IN HEALTH

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY